Indeed, since the high frequency of MYCN amplification in cancer and its role in driving and promoting tumorigenesis, as well as its space–temporal restricted expression during embryo development, precise N-Myc targeting would certainly result in successful therapeutics to support NB treatment (Figure 2) [18,96]. This evidence concerns the gene MYCN and neuroblastoma.